sanofi

# Results Q4 & FY 2024

January 30, 2025

# Forward-looking statements

This document contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, business transformations, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans”, “potential”, “outlook”, “guidance” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to complete capital markets or other transactions and/or obtain regulatory clearances, risks associated with developing standalone businesses, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, rends in exchange rates and prevailing interest rates, volatile economic and capital market conditions, cost containment initiatives and subsequent changes thereto, and the impact that pandemics, political disruption or armed conflicts or other global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2023. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

*Brand names appearing in this presentation are trademarks of Sanofi and/or its affiliates. Not all trademarks related to products under development have been approved as of the date of this presentation by the relevant health authorities.*

# Agenda

01 **Business**
Paul Hudson

02 **Finance**
François Roger

03 **Pipeline**
Houman Ashrafian

04 **Q&A**
Presenters and Olivier Charmeil, Brian Foard, Brendan O'Callaghan, Roy Papatheodorou, and Thomas Triomphe

# 2024: *a year of significant progress*

## *Strategy*

**A focused, science-driven biopharma company delivering innovative medicines and vaccines to patients**

### Progress in 2024

- Intention to sell a controlling stake in Opella consumer health at an attractive valuation[1]
- Further prioritizations in R&D

## *Business*

***11.3%***
*growth* in sales

***€4.5bn***
*sales* of nine newly launched medicines and vaccines

***One***
new blockbuster Beyfortus® (nirsevimab)

## *Pipeline*

Positive data for *phase 3 NMEs*
- fitusiran – hemophilia A/B
- rilzabrutinib – ITP
- tolebrutinib – nrSPMS

Positive data for *phase 3 LCM*
- Sarclisa – MM
- Dupixent – COPD, BP, CSU

New *phase 3-ready* programs
- duvakitug – IBD
- SP0202 – pneumococcal disease

All percentage changes at CER. 1. The proposed transaction is subject to finalization of definitive agreements and subject to obtaining regulatory approvals from the competent authorities.

# Q4: *double-digit* sales growth




- **Pharma launches:** continued strong performance
- **Dupixent:** strong prescription trends and volume growth across indications
- **Vaccines:** growth driven by Beyfortus

All percentage changes at CER. 1. ALTUVIIIO, Nexviazyme, Rezurock, Sarclisa, Cablivi, Xenpozyme, Enjaymo, Tzield.
On November 29, 2024, Recordati announced the closing of the acquisition of global rights to Enjaymo at which point Sanofi stopped booking in-market sales of the medicine.

# Launches: *11% of sales* in 2024

| *Sales (€m)* | *Q4* | *FY* |
|---|---|---|
| Beyfortus (nirsevimab) | 841 | 1,686 |
| ALTUVIIIO efanesoctocog alfa | 230 | 682 |
| Nexviazyme (avalglucosidase alfa) | 184 | 667 |
| REZUROCK (belumosudil) tablets | 132 | 470 |
| SARCLISA (isatuximab-irfc) | 130 | 471 |
| Cablivi caplacizumab-yhdp | 73 | 249 |
| Xenpozyme (olipudase alfa) | 38 | 151 |
| Enjaymo sutimlimab-jome | 22[1] | 105[1] |
| Tzield (teplizumab-mzwv) | 18 | 54 |
| | *€1,668m* | *€4,535m* |
| | *+78%* | *+106%* |

All percentage changes at CER. 1. On November 29, 2024, Recordati announced the closing of the acquisition of global rights to Enjaymo at which point Sanofi stopped booking in-market sales of the medicine.

# Dupixent: *exceeded €13bn target* in 2024 with strong growth to continue in approved and new indications

## *Sales (€bn)*




## *Strong performance*

**Q4**: continued strong **prescription growth** in all indications. Fewer business days/year-end GtN impacted US growth. **COPD** launches initiated

**FY**: delivered **>€13bn**, including **€3.5bn** outside the US

**#1 NBRx** market share across all indications[1]

## *Continued expansion of indications*

**Approval** – EoE (children) (EU)

**Resubmission acceptance** – CSU (US) (PDUFA Apr 18)

**Submission** – BP (US)[2]

All percentage changes at CER. 1. IQVIA data with internal projection. 2. Disclosed by Regeneron/awaiting regulatory submission acceptance.

# Vaccines: *growth* led by Beyfortus

## *Sales (€bn)*




Beyfortus (nirsevimab)

- **€1.7bn** in first full year of sales
- All-infant programs **>20** countries
- >80% reduction in RSV LRTI with real-world evidence in >100k infants[1]

**Influenza**

- Stronger leadership worldwide through increased market share and differentiated vaccines[2]

## *Q4: six clinical studies started*

**Phase 3**

- PCV21
- Fluzone HD (50 years+)

**Phase 1 and 2**

- Fluzone HD and Nuvaxovid
- Flublok and Nuvaxovid
- H5 pandemic flu
- H5 pandemic flu (mRNA)

**Fast-track designations (US)**

- Fluzone HD and Nuvaxovid
- Flublok and Nuvaxovid
- H5 pandemic flu (mRNA)

All percentage changes at CER. 1. Mallah N, et al. Lancet Infect Dis. 2024:S1473-3099(24)00811-9. Hsiao A, et al. Ann Allergy Asthma Immunol. 2024;42(22):126030. 2. Data on file.

# Sanofi: *ranked third* in the 2024 Access to Medicine Index

access to medicine index

*3rd*

vs.
8th previously

| | | |
|---|---|---|
| **Governance of access** | *Rank #1* | • Integrated access-to-medicine into overall corporate strategy and incentives |
| **R&D** | *Rank #3* | • Structured access planning framework |
| **Product delivery** | *Rank #5* | • Successful inclusive business model: Sanofi Global Health Unit<br>• Increased capacity building: technology transfer with Biovac in South Africa on IPV vaccine for African countries through UNICEF<br>• Access to insulin for Ghana and Delta State in Nigeria |

sanofi

# Finance

*Q4 & FY 2024*

*(new scope excluding Opella)*

# Q4: sales performance offset by *planned phasing* of expenses

| *(€m)* | *Q4 2023* | *Q4 2024* | *change* |
|---|---|---|---|
| **Net sales** | **9,687** | **10,564** | **+10.3%** |
| Other revenues | 1,381 | 856 | -37.9% |
| **Gross profit** | **7,443** | **7,844** | **+6.9%** |
| Gross margin | 76.8%[1] | 74.3%[1] | -2.5pp |
| R&D | (1,815) | (2,257) | +24.4% |
| SG&A | (2,466) | (2,648) | +7.9% |
| **Operating expenses** | **(4,281)** | **(4,905)** | **+14.9%** |
| Percentage of net sales | 44.2% | 46.4% | +2.2pp |
| Other operating income and expenses | (844) | (886) | +5.5% |
| **Business operating income** | **2,356** | **2,078** | **-7.7%** |
| Business operating margin | 24.3%[1] | 19.7%[1] | -4.6pp |
| Effective tax rate | 16.5% | 18.8% | +2.3pp |
| **Total business net income** | **1,935** | **1,642** | **-11.2%** |
| Average number of shares, million | 1,253.6 | 1,253.6 | |
| **Business EPS** | **1.54** | **1.31** | **-11.0%** |

### *Sales*

Growth driven by launches and Dupixent

### *Gross margin*

-2.5pp, due to COVID-19 revenue in 2023

### *Operating expenses*

R&D: increased activity level as planned
SG&A: positive leverage impact

### *Business operating income*

-7.7%, driven by absence of COVID-19 and higher operating expenses

### *Business EPS*

-11.0%, including a higher tax rate

All percentage changes at CER. 1. Margin at actual exchange rate.

# 2024: business EPS *above* guidance

| *(€m)* | *2023* | *2024* | *change* |
|---|---|---|---|
| **Net sales** | **37,817** | **41,081** | **+11.3%** |
| Other revenues | 3,801 | 3,205 | -13.3% |
| **Gross profit** | **28,999** | **31,091** | **+10.3%** |
| Gross margin | 76.7%[1] | 75.7%[1] | -1.0pp |
| R&D | (6,507) | (7,394) | +14.6% |
| SG&A | (8,933) | (9,183) | +4.5% |
| **Operating expenses** | **(15,440)** | **(16,577)** | **+8.8%** |
| Percentage of net sales | 40.8% | 40.4% | -0.4pp |
| Other operating income and expenses | (2,464) | (3,293) | +34.0% |
| **Business operating income** | **11,178** | **11,343** | **+7.6%** |
| Business operating margin | 29.6%[1] | 27.6%[1] | -2.0pp |
| Effective tax rate | 17.7% | 19.8% | +2.1pp |
| **Total business net income** | **9,076** | **8,912** | **+4.1%** |
| Average number of shares, million | 1,251.7 | 1,251.4 | |
| **Business EPS** | **7.25** | **7.12** | **+4.1%** |

### *Sales*

Growth driven by launches and Dupixent

### *Gross margin*

-1.0pp, due to COVID-19 revenue in 2023

### *Operating expenses*

R&D: investment in line with commitment
SG&A: positive leverage impact

### *Business operating income*

+7.6%, driven by higher gross profit and tight SG&A control

### *Business EPS*

+4.1%, ahead of guidance

All percentage changes at CER. 1. Margin at actual exchange rate.

# 2025: *business dynamics* to consider

## *FY 2025*

### *Sales*

**Sales FX impact**

Between +2% and +3%[1]

**US**

Usual Q1 impact from annual co-pay reset in specialty care, and introduction of IRA Part D redesign

**Other medicines**

Divestments €200 to €250m sales impact

**Beyfortus**

Further penetration and geographic expansion

### *P&L*

**Gross margin**

Increase

**Expenses**

R&D: slight increase due 2024 Sobi reimbursement

SG&A: slight increase in preparation for launches

**Capital gains (divestments)**

Around €500m

**Effective tax rate**

Broadly stable versus 2024

**EPS FX impact**

Between +2% and +3%[1]

**Guidance (at CER)**

*Sales* Growth at a **mid-to-high single-digit** percentage[2]

*Business EPS* Growth at a **low double-digit** percentage (before share buyback)

All percentage changes at CER. Barring unforeseen events. 1. Based on January 2025 average rates. 2. Excludes any impact from hyperinflation.

# Free cash flow: *impacted* by one-off items
(€bn)




Free cash flow definition in appendix 9 of the Q4 2024 results press release. 1. Excluding tax and factoring. 2. Other includes -94 of CAPEX net of depreciations, -137 of interests and tax paid, -610 of tax paid, -83 of restructuring and -149 of other items excluding tax.

# *Low* gearing
(€bn)




Credit ratings reaffirmed: Moody's A1/positive, S&P AA/stable, Scope AA/stable as of December 31, 2024. 1. Including derivatives used to manage net debt: €111m on December 31, 2023 and €213m on December 31, 2024. 2. Effective January 1, 2019, net debt does not include lease liabilities following the first-time application of IFRS16. 3. Before restructuring, acquisitions and disposals. 4. Includes acquisitions of intangible assets that are not exceeding a cap of €500 million per transaction (inclusive of all payments related to the transaction) of €1,434m, proceeds from disposal of -€805m, acquisition that are above a cap of €500 million per transaction (inclusive of all payments related to the transaction) of €2,509m, -€609m of proceeds net of taxes. 5. Including €302m use of funds from acquisition of treasury shares, €98m of impact on net debt of the reclassification of Opella business to "Assets held-for-sale", €439m of other items, -€187m of issuance of Sanofi shares, -€322m of net cash provided by/(used in) the discontinued Opella Business. 6. Business operating income non-GAAP.

# Capital allocation policy *confirmed*

## 1 *Organic investment*

## 2 *M&A/Business development*

## 3 *Growing dividend*

Dividend increase expected for the *30th consecutive year*




Proposed dividend
*€3.92*[1]
+4.3%

## 4 *Share buyback*

Sanofi intends to execute a share buyback program in 2025 of €5bn to be purchased preferably through block trades and in the open market with the purpose of cancellation.

*€5bn*

1. Subject to approval at the annual general meeting on April 30, 2025.

sanofi

# Pipeline



# 2024: *sustainable* progress across the pipeline

## *Scientific publications*




**9**

high-impact journals

(Cell, Lancet, Nature, and The New England Journal of Medicine)

## *Pipeline delivery*

**8** phase 3 **positive readouts**

**7** phase 3 **starts**

**6** **NMEs** entering the clinic

## *Regulatory successes*




*Strong pipeline progress across key indicators of R&D productivity*

As of December 31, 2024. 1. Includes the US, EU, Japan, and China.

# Sarclisa: *earlier use* and *subcutaneous* administration can unlock value for patients with multiple myeloma

## *GMMG-HD7 phase 3 study: transplant-eligible front-line patients 43% improvement in progression-free survival (PFS)*




- PFS: *30%* reduction in risk of disease progression or death (HR 0.70; 95% CI 0.52-0.95; p=0.0184) after induction therapy with Sarclisa-RVd
- Three-year PFS rate in the Sarclisa-RVd arm of *83%* compared to 75%

## *IRAKLIA phase 3 study: first data for subcutaneous formulation*

Subcutaneous fixed dose via on-body delivery system in combo with pomalidomide and dexamethasone *met co-primary, non-inferiority endpoints* compared to weight-based intravenous formulation.

Additional data from ongoing studies will support Sarclisa *subcutaneous* in combination with different standards of care in multiple lines of treatment.


**Regulatory submission planned in *H1 2025***

For additional details, please refer to the American Society of Hematology (ASH) 2024 Annual Meeting and Exposition presentation #364 (clinical trials identifier: NCT05804032). IRAKLIA clinical study identifier: NCT05405166.
enFuse, developed by Enable Injections, is an investigational on-body delivery system device and has not been approved by any regulatory authority or made available on the market.

# rilzabrutinib: potential *treatment* for patients with rare diseases

## *ITP: platelet response achieved in 65% of patients at 15 days*




- Primary endpoint demonstrated *durable platelet response in 23%* of patients compared to 0% at week 25 (95% CI, 16%-30%; p<0.0001)
- rilzabrutinib *significantly* improved clinical manifestations and fatigue, even in non-durable platelet responders
- High *unmet medical need* as current standard of care can be associated with safety risks and limitations in qualify of life



Regulatory decisions expected in *H2 2025* (US PDUFA Aug 29, EU, CN)

## *Taking a potentially disease-modifying treatment beyond ITP*

### Warm autoimmune hemolytic anemia[1]

- ASH 2024: rilzabrutinib phase 2 study showed *clinically meaningful* outcomes on response rate and disease markers
- Phase 3 plans underway

### IgG4-related disease[2]

- During Q4, rilzabrutinib phase 2 study showed *considerable* outcomes on disease flare and glucocorticoid sparing
- Next steps being considered

Potential to expand in *rare diseases*

For additional details, please refer to the American Society of Hematology (ASH) 2024 Annual Meeting and Exposition presentation #5 (clinical trial identifier: NCT04562766). 1. Clinical trial identifier NCT05002777. 2. Clinical trial identifier NCT04520451.

# duvakitug: *significant* and *clinically meaningful* benefits in IBD

## *Primary endpoints met in ulcerative colitis and Crohn's disease phase 2b study at week 14*

**ulcerative colitis**




**Crohn's disease**




*Full data* to be presented at ECCO in February

## *Phase 2b support further development as a treatment option for UC and CD*

- Based on a nominal comparison, and in absolute terms, the high-dose benefit seen in *UC* is the *largest* accross the TL1A class
- *Only* TL1A monoclonal antibody to show benefit in *CD* in phase 2
- *Favorable* safety and tolerability profile in both UC and CD, with low levels of anti-drug antibody[1]
- 2.3m ulcerative colitis and 1.8m Crohn's disease patients diagnosed, with *half* of them moderate-to-severe and eligible for biologics

Sanofi and Teva plan to initiate *phase 3* development in IBD, pending regulatory discussions

For additional details, please refer to the TEVA duvakitug investor call presentation (clinical study identifier: NCT05499130). All values met the pre-specified statistical criteria, probability of (TEV-'574 rate greater than PBO) >0.9. pvalues are based on one-sided test at a significant value of 0.1. 1. In phase 2a severe asthma (clinical study identifier: NCT04545385), for additional details, please refer to the P1061 poster presented at the 2024 Congress of the European Crohn's and Colitis Organisation.

# Pipeline: *increasing* news flow

## H1 2025

- balinatunfib – Psoriasis
- brivekimig – HS
- amlitelimab – HS
- amlitelimab – Asthma
- SAR447873 – GEP NETs
- SP0087 – Rabies
- rilzabrutinib – ITP (JP)
- tolebrutinib – SPMS (EU)
- Cerezyme – GD3 (US)
- Sarclisa – SC formulation (US, EU)
- Dupixent – COPD (JP)
- Dupixent – CSU (US, EU)
- fitusiran – Hemophilia A/B (US)
- Sarclisa – NDMM, TI (IMROZ) (JP, CN)
- MenQuadfi – Meningitis (six weeks+) (US)

## H2 2025

- balinatunfib – RA
- SAR447537 – AATD
- SP0230 – Meningitis
- SP0256 – RSV (older adults)
- itepekimab – COPD
- venglustat – Fabry disease
- venglustat – GD3
- tolebrutinib – PPMS
- Fluzone HD – Flu (50 years+)
- itepekimab – COPD (US, EU)
- SP0087 – Rabies (US, EU)
- Sarclisa – SC formulation (JP, CN)
- Dupixent – BP (US[1])
- Tzield – DO T1D (EU, CN)
- Tzield – EI T1D (EU)
- Rezurock – cGvHD, 3L (EU)
- fitusiran – Hemophilia A/B (CN)
- rilzabrutinib – ITP (US, EU, CN)
- tolebrutinib – SPMS (US[1])
- Sarclisa – NDMM, TE (HD7) (EU)

## 2026

- itepekimab – Bronchiectasis
- lunsekimig – Asthma
- lunsekimig – CRSwNP
- eclitasertib – UC
- frexalimab – SLE
- SAR444656 – HS/AD
- amlitelimab – AD
- Nexviazyme – IOPD
- riliprubart – CIDP
- SP0282 – E. coli sepsis
- SP0218 – Yellow fever
- SP0125 – RSV (toddlers)
- itepekimab – COPD (JP, CN)
- SAR447537 – AATD
- Nexviazyme – IOPD
- venglustat – GD3
- venglustat – Fabry
- riliprubart – CIDP
- tolebrutinib – PPMS (US, EU)
- Fluzone HD – Flu (50 years+)
- SP0218 – Yellow fever

Key pipeline news flow only. For abbreviations, please see slide 41. 1. Awaiting regulatory acceptance in the US.

Phase 2 data readout | Phase 3 data readout | Regulatory submission | Regulatory decision

# Q&A session

*To ask a question*

**By zoom** 

Click on the **Raise hand** icon

Check your audio device is well connected

**By phone** 

Raise and lower your hand: dial *9

Unmute and mute your microphone: dial *6

**Any problems?** 

Email us: investor.relations@sanofi.com

sanofi

# Finance appendices

(new scope excluding Opella)

# Sales *biopharma*

| | *Q4 2024 (€m)* | *change* | *FY 2024 (€m)* | *change* |
|---|---|---|---|---|
| Dupixent | 3,458 | 16.0% | 13,072 | 23.1% |
| RSV vaccines (Beyfortus) | 841 | 106.6% | 1,686 | 214.4% |
| Polio/Pertussis/Hib vaccines & Boosters | 632 | 10.8% | 2,741 | 1.2% |
| Influenza vaccines | 454 | -36.8% | 2,555 | -1.3% |
| Lantus | 439 | 63.4% | 1,628 | 20.8% |
| Toujeo | 290 | 6.5% | 1,227 | 13.4% |
| Fabrazyme | 269 | 12.4% | 1,047 | 9.1% |
| Meningitis, Travel and Endemic vaccines | 249 | -4.2% | 1,316 | 5.4% |
| Lovenox | 231 | -7.6% | 982 | -7.0% |
| ALTUVIIIO | 230 | 143.6% | 682 | 330.2% |
| Plavix | 211 | -16.9% | 914 | -0.4% |
| Nexviazyme/Nexviadyme | 184 | 42.0% | 667 | 61.2% |
| Cerezyme | 171 | 33.8% | 742 | 20.3% |
| Alprolix | 169 | 19.0% | 588 | 9.6% |
| Rezurock | 132 | 53.5% | 470 | 51.6% |
| Myozyme | 132 | -17.0% | 671 | -12.3% |
| Sarclisa | 130 | 30.1% | 471 | 29.7% |
| Kevzara | 126 | 21.0% | 424 | 21.0% |
| Thymoglobulin | 125 | 15.2% | 492 | 7.3% |
| Praluent | 110 | -6.8% | 483 | 15.2% |

All percentage changes at CER.

# Currency impact[1]

## *Sales (€m)*




## *Business EPS (€)*




1. Reflecting the new scope of reporting excluding Opella.

# Currency sensitivity and exposure

## *2025 business EPS currency sensitivity*

| currency | change | business EPS sensitivity |
|---|---|---|
| US Dollar | + 0.05 USD/EUR | - EUR 0.18 |
| Japanese Yen | + 5 JPY/EUR | - EUR 0.02 |
| Chinese Yuan | + 0.2 CNY/EUR | - EUR 0.02 |
| Brazilian Real | + 0.4 BRL/EUR | - EUR 0.01 |

## *Currency average rates*

| | Q4 2023 | Q4 2024 | change |
|---|---|---|---|
| €/US Dollar | 1.076 | 1.067 | -0.8% |
| €/Yen | 159.030 | 162.434 | +2.1% |
| €/Yuan | 7.778 | 7.685 | -1.2% |
| €/Real | 5.329 | 6.229 | +16.9% |
| €/Ruble | 99.644 | 106.724 | +7.1% |

## *Currency exposure on Q4 2024 sales*



# Accounting treatment of SP0202 (pneumococcal disease 21-valent conjugate) - updated December 2024

| | | *World excluding South Korea* | *South Korea* |
|---|---|---|---|
| **Net sales** | | Sanofi consolidates net sales | SK bioscience consolidates net sales |
| **Cost of sales** | | Sanofi consolidates cost of sales<br>Sanofi will pay SK bioscience royalties on net sales | SK bioscience consolidates cost of sales |
| **R&D** | | R&D costs are shared 50% between the parties | |
| **SG&A** | | Sanofi books 100% of the costs | SK bioscience bears 100% of the costs |
| **Intangible asset** (amortized below BNI over useful life) | **Upfront** | Sanofi paid €50m to SK bioscience upon closing of the updated agreement (Q1 2025) | |
| | **Development, regulatory and sales milestones** | Sanofi will pay up to €300m of development, regulatory and sales milestones | |

Above BNI  Below BNI

sanofi

# Pipeline appendices



# What's next: Immunology




As of December 31, 2024. For abbreviations, please see slide 41. Illustrative.

# What's next: Vaccines




As of December 31, 2024. For abbreviations, please see slide 41. Illustrative.

# Pipeline: *Q4 appendix changes*

## New in

### *Regulatory*

Submission **Dupixent** – Chronic spontaneous urticaria (US)

Submission **rilzabrutinib** – Immune thrombocytopenia (US, EU, CN)

Submission **Sarclisa** – NDMM, TE (HD7) (EU)

### *Phase 3*

**Dupixent** – Lichen simplex chronicus

**SP0202** – Pneumococcal disease

**Fluzone HD** – Flu (50 years+)

### *Phase 2*

**balinatunfib** – Crohn's disease

**lunsekimig** – High-risk asthma

**SAR447873** – GEP NETs

**SP0335** – Flu (H5 pandemic)

### *Phase 1*

**SAR446959** – Knee osteoarthritis

**SP0287** – Fluzone HD+COVID-19

**SP0287** – Flublok+COVID-19

**SP0289** – Flu (H5 pandemic)

### *Designations*

US ODD **SAR443579** – AML

FTD **Fluzone HD+Nuvaxovid** – Flu+COVID-19

FTD **Flublok+Nuvaxovid** – Flu+COVID-19

FTD **SP0289** – Flu (H5 pandemic)

FTD **SP0256** – RSV+hMPV (older adults)

US BTD **tolebrutinib** – nrSPMS

US BTD **SAR447873** – GEP NETs

## Removed from

### *Regulatory*

Approval **Dupixent** – EoE (children) (EU)

Approval **Cerdelga** – GD1 (children) (EU)

Approval **Sarclisa** – NDMM, TI (IMROZ) (EU)

### *Phase 3*

**Dupixent** – CSU (US)

**rilzabrutinib** – ITP

**tolebrutinib** – RMS

### *Phase 2*

**SP0202** – Pneumococcal disease

**Fluzone HD** – Flu (children)

### *Phase 1*

**SAR445611** – Inflammatory indication

**SAR444200** – Solid tumors

**pegenzileukin** – Cancer, in combination

As of December 31, 2024. For collaborations (superscripted by capital letters), please see slide 40. For abbreviations, please see slide 41.

# Pipeline: *registration and phase 3*

## Registration

| | | |
|---|---|---|
| **Dupixent[A]** | IL4xIL13 mAb | Chronic obstructive pulmonary disease (JP) |
| | | Chronic spontaneous urticaria (US, EU) |
| **fitusiran[1]** | RNAi targeting anti-thrombin | Hemophilia A and B (US, CN) |
| **rilzabrutinib** | BTK inhibitor | Immune thrombocytopenia (US, EU, CN) |
| **Sarclisa** | CD38 mAb | NDMM, TI (IMROZ) (JP, CN) |
| | | NDMM, TE (HD7) (EU) |
| **MenQuadfi[1]** | 4-valent (ACWY) conjugate | Meningitis (six weeks+) (US) |

## Phase 3

### *Immunology*

| | | |
|---|---|---|
| **Dupixent[A]** | IL4xIL13 mAb | Bullous pemphigoid[5] |
| | | Chronic pruritus of unknown origin |
| | | Eosinophilic gastritis |
| | | Lichen simplex chronicus |
| **itepekimab[A]** | IL33 mAb | Chronic obstructive pulmonary disease |
| **amlitelimab** | OX40L mAb | Atopic dermatitis |
| **Rezurock** | ROCK2 inhibitor | Chronic lung allograft dysfunction |
| | | Chronic graft-versus-host disease, 1L |
| **Tzield** | CD3 mAb | Type 1 diabetes |

### *Neurology*

| | | |
|---|---|---|
| **tolebrutinib** | BTK inhibitor | Non-relapsing secondary progressive MS[5] |
| | | Primary progressive MS |
| **frexalimab[B,2]** | CD40L mAb | Relapsing MS |
| | | Non-relapsing secondary progressive MS |
| **riliprubart[3]** | C1s inhibitor | SOC-refractory CIDP |
| | | IVIg-treated CIDP |

### *Rare diseases*

| | | |
|---|---|---|
| **Nexviazyme** | Enzyme replacement therapy | Pompe disease infantile onset (US) |
| **venglustat** | Oral GCS inhibitor | Fabry disease |
| | | Gaucher disease type 3 |

### *Oncology*

| | | |
|---|---|---|
| **Sarclisa** | CD38 mAb | NDMM, TE (HD7) (US) |
| | | NDMM, TE (IsKia) |
| | | Smoldering MM (ITHACA) |
| | CD38 mAb subcutaneous | R/R MM (IRAKLIA) |

### *Vaccines*

| | | |
|---|---|---|
| **SP0087** | Vero cell | Rabies |
| **SP0125** | Live attenuated | RSV (toddlers) |
| **Fluzone HD[4]** | Multivalent inactivated | Flu (50 years+) |
| **SP0202[C]** | 21-valent conjugate | Pneumococcal disease |
| **SP0282[D]** | 9-valent conjugate | E. coli sepsis |

As of December 31, 2024. For collaborations (superscripted by capital letters), please see slide 40. For abbreviations, please see slide 41. Pediatric and adolescents' indication extensions are not included.
1. Currently in phase 3 in the EU. 2. Also known as SAR441344. 3. Also known as SAR445088. 4. Also known as SP0178. 5. Awaiting regulatory acceptance in the US.

# Pipeline: *phase 2*

## *Immunology*

| | | |
|---|---|---|
| **Dupixent**[A] | IL4xIL13 mAb | Ulcerative colitis |
| **itepekimab**[A] | IL33 mAb | Bronchiectasis |
| **amlitelimab** | OX40L mAb | Alopecia areata |
| | | Asthma |
| | | Celiac disease |
| | | Hidradenitis suppurativa |
| | | Systemic sclerosis |
| **rilzabrutinib** | BTK inhibitor | Asthma |
| | | Chronic spontaneous urticaria |
| | | IgG4-related disease |
| **frexalimab**[B,1] | CD40L mAb | Systemic lupus erythematosus |
| | | Type 1 diabetes |
| **balinatunfib**[2] | Oral TNFR1 signaling inhibitor | Psoriasis |
| | | Rheumatoid arthritis |
| | | Crohn's disease |
| **lunsekimig**[3] | IL13xTSLP Nanobody® VHH | Asthma |
| | | High-risk asthma |
| | | Chronic rhinosinusitis with nasal polyps |
| **eclitasertib**[E,4] | RIPK1 inhibitor | Ulcerative colitis |
| **SAR444656**[F,5] | IRAK4 degrader | Atopic dermatitis |
| | | Hidradenitis suppurativa |
| **brivekimig**[6] | TNFaxOX40L Nanobody® VHH | Hidradenitis suppurativa |
| **duvakitug**[G,7] | TL1A mAb | Crohn's disease |
| | | Ulcerative colitis |
| **riliprubart**[8] | C1s inhibitor | Antibody-mediated rejection |

## *Rare diseases*

| | | |
|---|---|---|
| **rilzabrutinib** | BTK inhibitor | Warm autoimmune hemolytic anemia |
| **SAR447537**[9] | AAT fusion protein | Alpha-1 antitrypsin deficiency |

## *Oncology*

| | | |
|---|---|---|
| **Sarclisa** | CD38 mAb | R/R MM |
| **SAR443579**[H] | Trifunctional anti-CD123 NK-cell engager | Acute myeloid leukemia |
| **SAR447873**[I,10] | SSTR targeting alpha-emitter therapy | Gastroenteropancreatic neuroendocrine tumors |

## *Vaccines*

| | | |
|---|---|---|
| **SP0218** | Vero cell | Yellow fever |
| **SP0230** | 5-valent (ABCWY) | Meningitis |
| **SP0256 (1)** | mRNA | RSV (older adults) |
| **SP0335** | Inactivated adjuvanted | Flu (H5 pandemic) |

As of December 31, 2024. For collaborations (superscripted by capital letters), please see slide 40. For abbreviations, please see slide 41. Pediatric and adolescents' indication extensions are not included.
1. Also known as SAR441344. 2. Also known as SAR441566. 3. Also known as SAR443765. 4. Also known as SAR443122/DNL758. 5. Also known as KT474. 6. Also known as SAR442970. 7. Also known as SAR447189/TEV'574.
8. Also known as SAR445088. 9. Formerly known as INBRX-101. 10. Also known as 212Pb-dotamtate/AlphaMedix.

# Pipeline: *phase 1*

## *Immunology*

| | | |
|---|---|---|
| **SAR444336** | Non-beta IL2 Synthorin™ | Inflammatory indication |
| **SAR445399**[1] | IL1R3 mAb | Inflammatory indication |
| **SAR446422** | CD28xOX40 bispecific Ab | Inflammatory indication |
| **SAR446959** | MMP13xADAMTS5xCAP Nanobody® VHH | Knee osteoarthritis |

## *Neurology*

| | | |
|---|---|---|
| **SAR446159**[J,2] | SynucleinxIGF1R mAb | Parkinson's disease |

## *Oncology*

| | | |
|---|---|---|
| **SAR445514**[H] | Trifunctional anti-BCMA NK-cell engager | R/R MM |
| **SAR444881**[K] | ILT2 mAb | Solid tumors |
| **SAR445877**[3] | PD1xIL15 fusion protein | Solid tumors |
| **SAR445953**[L] | CEACAM5-Topo1 ADC | Colorectal cancer |

## *Vaccines*

| | | |
|---|---|---|
| **SP0237** | mRNA | Flu |
| **SP0287** | Fluzone HD+Nuvaxovid | Flu+COVID-19 |
| **SP0287** | Flublok+Nuvaxovid | Flu+COVID-19 |
| **SP0289** | mRNA | Flu (H5 pandemic) |
| **SP0256 (2)** | mRNA | RSV+hMPV (older adults) |
| **SP0291** | mRNA | RSV+hMPV+PIV3 (older adults) |
| **SP0268** | mRNA | Acne |

As of December 31, 2024. For collaborations (superscripted by capital letters), please see slide 40. For abbreviations, please see slide 40. Pediatric and adolescents' indication extensions are not included.
1. Also known as MAB212, in-licensed from MAB Discovery. 2. Also known as ABL301. 3. Also known as KD050. 4. Also known as SAR444245.

# Pipeline: *regulatory designations* since 2020

## *Orphan-drug*

- **Dupixent** – BP, EoE (US)
- **ALTUVIIIO** – hemophilia A (US, EU)
- **fitusiran** – hemophilia A/B (US, EU)
- **rilzabrutinib** – ITP (US, EU, JP)
- **Cerdelga** – Gaucher (US)
- **Nexviazyme** – Pompe (US, JP)
- **Xenpozyme** – ASMD (US, EU, JP)
- **venglustat** – Fabry, Gaucher (US, EU, JP)
- **Rezurock** – cGvHD (US)
- **riliprubart** – CIDP (US, EU)
- **Sarclisa** – MM (US)
- **SAR443579** – AML (US)

## *Fast-track (US)*

- **itepekimab** – COPD
- **ALTUVIIIO** – hemophilia A
- **fitusiran** – hemophilia A/B
- **rilzabrutinib** – ITP
- **Nexviazyme** – Pompe
- **Xenpozyme** – ASMD
- **Venglustat** – Fabry
- **AAT recombinant Fc** – AATD
- **CD123 NKCE** – AML
- **Beyfortus** – RSV
- **SP0125** – RSV (toddlers)
- **SP0202** – pneumococcal disease
- **SP0087** – rabies
- **Fluzone HD+Nuvaxovid** – Flu+COVID-19
- **Flublok+Nuvaxovid** – Flu+COVID-19
- **SP0289** – Flu (H5 pandemic)
- **SP0256** – RSV+hMPV (older adults)

## *Breakthrough-therapy*

- **Dupixent** – AD (US)
- **Dupixent** – COPD (US)
- **Dupixent** – EoE (US)
- **Rezurock** – cGvHD (US)
- **ALTUVIIIO** – hemophilia A (US, CN)
- **fitusiran** – hemophilia A/B (US)
- **Nexviazyme** – Pompe (US)
- **Xenpozyme** – ASMD (US)
- **tolebrutinib** – nrSPMS (US)
- **riliprubart** – CIDP (CN)
- **SAR447873** – GEP NET (US)
- **Beyfortus** – RSV (US, CN)

## *PRIME (EU)*

- **Xenpozyme** – ASMD
- **Beyfortus** – RSV
- **SP0125** – RSV (toddlers)

## *SAKIGAKE (JP)*

- **Xenpozyme** – ASMD

## *Priority review*

- **Dupixent** – AD, PN (US, CN), EoE, COPD, CRSwNP adolescents (US)
- **Kevzara** – RA (US)
- **TZIELD** – T1D (CN)
- **Rezurock** – cGvHD (US)
- **ALTUVIIIO** – hemophilia A (US)
- **Nexviazyme** – Pompe (US, JP, CN)
- **Cablivi** – aTTP (JP)
- **Xenpozyme** – ASMD (US)
- **Sarclisa** – NDMM, 1L TI (US)
- **Fexinidazole** – HAT (US)
- **Beyfortus** – RSV (CN)

## *Accelerated assessment*

- **Dupixent** – PN (CN)
- **Xenpozyme** – ASMD (EU)
- **Beyfortus** – RSV (EU)

As of December 31, 2024. For abbreviations, please see slide 41.

# Pipeline: main clinical studies *across disease areas*

## *Immunology*

**Dupixent** (IL4xIL13 mAb)
- BP (NCT04206553)
- CPUO (NCT05263206)
- CSU (Study B: NCT04180488)
- Ulcerative colitis (NCT05731128)
- Eosinophilic gastritis (ENGAGE: NCT05831176)
- Lichen simplex chronicus (STYLE 1: NCT06687967, STYLE 2: NCT06687980)

**amlitelimab** (OX40L mAb)
- Atopic dermatitis (COAST 1: NCT06130566, COAST 2: NCT06181435, SHORE: NCT06224348, AQUA: NCT06241118, ESTUARY: NCT06407934)
- Asthma (TIDE-Asthma: NCT05421598)
- Hidradenitis suppurativa (NCT06118099)
- Alopecia areata (NCT06444451)
- Celiac disease (NCT06557772)
- Systematic sclerosis (CONQUEST: NCT06195072)

**itepekimab** (IL33 mAb)
- COPD (AERIFY-1:NCT04701983, AERIFY-2: NCT04751487, AERIFY-3: NCT05326412)
- Bronchiectasis (NCT06280391)

**rilzabrutinib** (BTK inhibitor)
- Asthma (NCT05104892)
- Chronic spontaneous urticaria (RILECSU: NCT05107115)
- IgG4-related disease (NCT04520451)

**frexalimab** (CD40L mAb)
- Systemic lupus erythematosus (APATURA: NCT05039840)
- Type 1 diabetes (FABULINUS: NCT06111586)

**balinatunfib** (oral TNFR1si)
- Psoriasis (SPECIFI-PSO: NCT06073119)
- Rheumatoid arthritis (SPECIFI-RA: NCT06073093)
- Crohn's disease (SPECIFIC-CD: NCT06637631)

**duvakitug** (TL1A mAb)
- Crohn's disease, ulcerative colitis (RELIEVE UCCD: NCT05499130)

**eclitasertib** (RIPK1 inhibitor)
- Ulcerative colitis (NCT05588843)

**lunsekimig** (IL13xTSLP Nanobody VHH®)
- Moderate to severe asthma (AIRCULES: NCT06102005)
- High-risk asthma (AIRLYMPUS: NCT06676319)
- Chronic rhinosinusitis with nasal polyps (NCT06454240)

**brivekimig** (TNFaxOX40L Nanobody VHH®)
- Hidradenitis suppurativa (HS OBTAIN NCT05849922)

**SAR444656** (IRAK4 degrader)
- Atopic dermatitis (ADVANTA: NCT06058156)
- Hidradenitis suppurativa (ZEN: NCT06028230)

**SAR444336** (non-beta IL2 Synthorin™)
- Inflammatory indication (NCT05876767)

**SAR445399** (IL1R3 mAb)
- Inflammatory indication

**SAR446422** (CD28xOX40 bispecific Ab)
- Inflammatory indication (NCT)

**SAR446959** (MMP13xADAMTS5xCAP Nanobody® VHH)
- Knee osteoarthritis (NCT06704932)

**Rezurock** (ROCK2 inhibitor)
- Chronic lung allograft dysfunction (ROCKaspire: NCT06082037)
- Chronic graft-versus-host disease, 1L (ROCKnrol-1: NCT06143891)

**Tzield** (CD3 mAb)
- Stage 2 Type 1 diabetes (PETITE-T1D: NCT05757713)
- Stage 3 Type 1 diabetes (PROTECT Extension: NCT04598893)

**riliprubart** (C1s inhibitor)
- Antibody-mediated rejection (NCT05156710)

## *Rare diseases*

**Nexviazyme** (enzyme replacement therapy)
- Pompe disease infantile onset (Mini-COMET: NCT03019406)

**Venglustat** (oral GCS inhibitor)
- Fabry disease (PERIDOT: NCT05206773, CARAT: NCT05280548)
- Gaucher disease type 3 (LEAP2MONO: NCT05222906)

**Fitusiran** (RNAi targeting anti-thrombin)
- Hemophilia A and B (ATLAS-OLE: NCT03754790, ATLAS-PEDS: NCT03974113)

**rilzabrutinib** (BTK inhibitor)
- ITP (LUNA 3: NCT04562766)
- wAIHA (NCT05002777)

**SAR447537** (AAT fusion therapy)
- Alpha-1 antitrypsin deficiency (NCT05856331, ELEVAATE OLE: NCT05897424)

## *Neurology*

**tolebrutinib** (BTK inhibitor)
- Non-relapsing SPMS (HERCULES: NCT04411641)
- PPMS (PERSEUS: NCT04458051)

**frexalimab** (CD40L mAb)
- Relapsing MS (FREXALT: NCT06141473)
- Non-relapsing SPMS (FREVIVA: NCT06141486)

**riliprubart** (C1s inhibitor)
- SOC-refractory CIDP (MOBILIZE: NCT06290128)
- IVIg-treated CIDP (VITALIZE: NCT06290141)

**SAR446159** (synucleinxIGF1R mAb)
- Parkinson's disease (NCT05756920)

As of December 31, 2024. For abbreviations, please see slide 41. Illustrative.

# Pipeline: main clinical studies *across disease areas*

## *Oncology*

**Sarclisa** (CD38 mAb)
- MM, 1L TI (IMROZ: NCT03319667)
- MM, 1L TE (GMMG-HD7: NCT03617731)
- MM, 1L TE (IsKia: NCT04483739)
- Smoldering MM (NCT04270409)
- R/R MM (IRAKLIA: NCT05405166)

**SAR443579** (trifunctional anti-CD123 NK-cell engager)
- Acute myeloid leukemia (NCT05086315, NCT06508489)

**SAR447873** (SSTR targeting alpha-emitter therapy)
- Neuroendocrine tumors (ALPHAMEDIX02: NCT05153772)

**SAR445514** (trifunctional anti-BCMA NK-cell engager)
- R/R MM (NCT05839626)

**SAR444881** (ILT2 mAb)
- Solid tumors (NCT04717375)

**SAR445877** (PD1xIL15 fusion protein)
- Solid tumors (NCT05584670)

**SAR445953** (CEACAM5-Topop1 ADC)
- Colorectal cancer (NCT06131840)

## *Vaccines*

**SP0087** *(vero cell)*
- Rabies (NCT04127786)

**SP0125** *(live attenuated)*
- RSV (toddlers) (CORAL: NCT06397768, OPAL: NCT06705140)

**Fluzone HD** (inactivated quadrivalent)
- Flu 50y+ (NCT06641180)

**SP0202** *(*21-valent conjugate*)*
- Pneumococcal disease (NCT06736041)

**SP0282** *(*9-valent conjugate*)*
- E. coli sepsis (NCT04899336)

**SP0218** *(vero cell)*
- Yellow fever (VYF02: NCT04942210)

**SP0230** *(*5-valent (ABCWY)*)*
- Meningitis (NCT06128733)

**SP0256** *(mRNA)*
- RSV+hMPV (older adults) (NCT06134648, NCT06686654)

**SP0237** *(mRNA)*
- Flu (NCT06744205)

**SP0287** *(Fluzone HD+Nuvaxovid)*
- Flu+COVID-19 (NCT06695117)

**SP0287** *(Flublok+Nuvaxovid)*
- Flu+COVID-19 (NCT06695130)

**SP0289** *(mRNA)*
- Flu (H5 pandemic) (NCT06727058)

**SP0335** *(inactivated adjuvanted)*
- Flu pandemic (NCT06560151)

**SP0291** *(mRNA)*
- RSV+hMPV+PIV3 (older adults) (NCT06604767)

**SP0268** *(mRNA)*
- Acne (NCT06316297)

As of December 31, 2024. For abbreviations, please see slide 41. Illustrative.

# Collaborations

| Ref | Name | Developed in collaboration with… |
|---|---|---|
| A | **Dupixent**<br>**itepekimab**<br>**Kevzara** | Regeneron |
| B | **frexalimab** | ImmuNext |
| C | **SP0202** | SK bioscience |
| D | **SP0282** | Janssen Pharmaceuticals |
| E | **eclitasertib** | Denali |
| F | **SAR444656** | Kymera |
| G | **duvakitug** | Teva Pharmaceuticals |
| H | **SAR443579**<br>**SAR445514** | Innate Pharma |
| I | **SAR447873** | RadioMedix, Orano Med |
| J | **SAR446159** | ABL Bio |
| K | **SAR444881** | Biond Biologics |
| L | **SAR445953** | Pfizer |
| | **Beyfortus** | AstraZeneca |
| | **ALTUVIIIO** | Swedish Orphan Biovitrum AB (Sobi) |

# Abbreviations

| | |
|---|---|
| **AAT** | Alpha-1-antitrypsine |
| **AATD** | Alpha-1-antitrypsine deficiency |
| **Ab** | Antibody |
| **AD** | Atopic dermatitis |
| **ADC** | Antibody drug conjugate |
| **AML** | Acute myeloid leukemia |
| **ASMD** | Acid sphingomyelinase deficiency |
| **aTTP** | Acquired thrombotic thrombocytopenic purpura |
| **BCMA** | B-cell maturation antigen |
| **BP** | Bullous pemphigoid |
| **BTK** | Bruton's tyrosine kinase |
| **CD** | Cluster of differentiation |
| **CEACAM5** | Carcinoembryonic antigen cell adhesion molecule 5 |
| **cGvHD** | Chronic graft-versus-host disease |
| **CIDP** | Chronic inflammatory demyelinating polyneuropathy |
| **COPD** | Chronic obstructive pulmonary disease |
| **CPUO** | Chronic pruritus of unknown origin |
| **CRSwNP** | Chronic rhinosinusitis without nasal polyps |
| **CSU** | Chronic spontaneous urticaria |
| **DO** | Delay onset |
| **EI** | Early intervention |
| **EoE** | Eosinophilic esophagitis |
| **GCS** | Glucosylceramide synthase |
| **GD1** | Gaucher disease type 1 |
| **GD3** | Gaucher disease type 3 |
| **GEP-NETs** | Gastroenteropancreatic neuroendocrine tumors |

| | |
|---|---|
| **HAT** | Human African trypanosomiasis |
| **HD** | High dose |
| **hMPV** | Human metapneumovirus |
| **HS** | Hidradenitis suppurativa |
| **IBD** | Inflammatory bowel disease |
| **IGF1R** | Insulin-like growth factor 1 receptor |
| **IL** | Interleukin |
| **ILT2** | Ig-like transcript 2 |
| **IOPD** | Infante-onset Pompe disease |
| **IPV** | Inactivated poliovirus vaccine |
| **IRA** | (US) Inflation Reduction Act |
| **IRAK4** | Interleukin 1 receptor associated kinase 4 |
| **ITP** | Immune thrombocytopenia |
| **IVIg** | Intravenous immunoglobulin |
| **LCM** | Life-cycle management |
| **mAb** | Monoclonal antibody |
| **MM** | Multiple myeloma |
| **mRNA** | Messenger RNA |
| **MS** | Multiple sclerosis |
| **NBRx** | New-to-brand prescription |
| **NDMM** | Newly diagnosed multiple myeloma |
| **NK** | Natural killer |
| **NKCE** | Natural killer cell engager |
| **NME** | New molecular entity |
| **nrSPMS** | Non-relapsing secondary progressive multiple sclerosis |

| | |
|---|---|
| **PCV** | Pneumococcal conjugate vaccine |
| **pJIA** | Polyarticular juvenile idiopathic arthritis |
| **PMR** | Polymyalgia rheumatica |
| **PN** | Prurigo nodularis |
| **PPMS** | Primary progressive multiple sclerosis |
| **RA** | Rheumatoid arthritis |
| **RIPK1** | Receptor-interacting serine/threonine-protein kinase 1 |
| **RMS** | Relapsing multiple sclerosis |
| **RNAi** | RNA interference |
| **ROCK2** | Rho associated coiled-coil containing protein kinase 2 |
| **R/R** | Relapsed/refractory |
| **RSV** | Respiratory syncytial virus |
| **SC** | Subcutaneous |
| **sJIA** | Systemic juvenile idiopathic arthritis |
| **SLE** | Systematic lupus erythematosus |
| **SSTR** | Somatostatin receptor |
| **SOC** | Standard of care |
| **T1D** | Type 1 diabetes |
| **TE** | Transplant eligible |
| **TI** | Transplant ineligible |
| **TL1A** | Tnf-like ligand 1A |
| **TNF** | Tumor necrosis factor |
| **TSLP** | Thymic stromal lymphopoietin |
| **T1D** | Type 1 diabetes |
| **UC** | Ulcerative colitis |
| **wAIHA** | Warm autoimmune hemolytic anemia |


sanofi